SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.
$CRNX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2026 | $67.00 | Neutral → Buy | Goldman |
| 7/10/2025 | $36.00 | Neutral | Goldman |
| 3/25/2025 | $60.00 | Buy | Stifel |
| 2/11/2025 | Buy | TD Cowen | |
| 2/4/2025 | Peer Perform | Wolfe Research | |
| 1/22/2025 | $55.00 | Hold → Buy | Jefferies |
| 3/6/2024 | $68.00 | Buy | Citigroup |
| 1/16/2024 | $50.00 | Overweight | Morgan Stanley |
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing's syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate atumelnant, will be presented at t
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY. Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on dis
Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00
Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00
Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins
Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business & Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline. Ms. Dear
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026. "We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Pa
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 7 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:173777518 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that par
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)